Safety Study of Somatrogon Injections for Children with Pediatric Growth Hormone Deficiency in India

What this Trial Is About

This research aims to learn about the safety of Somatrogon, a long-acting growth hormone, for treating pediatric growth hormone deficiency p GHD in children aged 3 to 17 years in India. Pediatric GHD is a condition where the body produces too little growth hormone, leading to shorter height in affected children. The study focuses on participants confirmed with p GHD and prescribed Somatrogon injections. Participants will receive Somatrogon as part of their routine clinical care, and the study will observe their health over a period of up to three years. The safety will be monitored by tracking any side effects, expected or unexpected, that occur after taking Somatrogon. Follow-up will be conducted through clinic visits or phone calls, but regular clinic visits are not mandatory. During the study, researchers will collect information on adverse events and treatment adherence, including missed injections, over the three-year period. The goal is to understand the safety profile of Somatrogon in this patient group. Participants involvement includes providing informed consent, and assessments will be conducted as part of their usual care without additional interventions specifically for the study.

A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.